10-KPeriod: FY2008

DEXCOM INC Annual Report, Year Ended Dec 31, 2008

Filed March 5, 2009For Securities:DXCM

Summary

DexCom, Inc. (DXCM) in its March 5, 2009, 10-K filing, reveals a company in its early commercialization phase, focused on developing and selling continuous glucose monitoring (CGM) systems. The company has received FDA approval for its SEVEN and SEVEN PLUS systems, designed for up to seven days of use, and is working towards broader market acceptance. However, DexCom faces significant challenges including a limited operating history, the need for market acceptance by physicians and patients, potential manufacturing and supply chain issues, and the critical hurdle of securing adequate reimbursement from third-party payors, which is not yet broadly established. Financially, DexCom has incurred substantial net losses since inception, with a significant accumulated deficit. The company relies on ongoing financing, having recently completed a public stock offering. A major concern highlighted is the significant debt obligation from convertible senior notes, which could lead to dilution for existing shareholders upon conversion. Additionally, DexCom is embroiled in a patent infringement lawsuit with Abbott Diabetes Care, which poses a substantial risk to its business operations and financial stability.

Key Highlights

  • 1DexCom has received FDA approval for its SEVEN and SEVEN PLUS continuous glucose monitoring systems, indicating product development progress.
  • 2The company faces substantial financial challenges, including a significant accumulated deficit and ongoing net losses, requiring continuous financing.
  • 3Securing broad reimbursement from third-party payors is a critical challenge for widespread product adoption and revenue generation.
  • 4DexCom is involved in a significant patent infringement lawsuit with Abbott Diabetes Care, which carries substantial legal costs and potential business impairment.
  • 5The company's ability to scale manufacturing and establish effective sales and distribution channels are key operational risks.
  • 6A $60 million Convertible Senior Note issuance in March 2007 poses potential dilution risk to existing shareholders.

Frequently Asked Questions

DexCom's primary products are continuous glucose monitoring (CGM) systems. The company had received FDA approval for its SEVEN system (7-day use) and was launching its third-generation system, SEVEN PLUS, in early 2009. Their earlier STS system (3-day use) had been discontinued.

DexCom faces significant financial risks including substantial accumulated losses since inception, a dependence on external financing, and a large debt burden from convertible senior notes that could dilute existing shareholders. The company also notes that global economic uncertainty makes predicting product demand difficult.

Key challenges include physician and patient acceptance, which depends on demonstrating safety, efficacy, cost-effectiveness, and ease of use. A significant hurdle is the lack of broad reimbursement from third-party payors, meaning patients often bear the full cost. The invasiveness of the sensor compared to finger-stick tests and physician reluctance to change established practices also pose challenges.

Abbott Diabetes Care filed a patent infringement lawsuit against DexCom. The litigation involves multiple patents and is currently stayed pending reexamination proceedings at the U.S. Patent and Trademark Office. DexCom believes the claims are without merit but acknowledges significant costs and potential adverse effects regardless of the outcome, including the possibility of an injunction that could halt product sales.